NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.

Poly-L-Lactic Acid
Authors

Christine K. Sickles1; Ali Nassereddin2; Gary P. Gross3.

Affiliations
1 Lewis Gale Hospital Montgomery
2 WakeMed Health and Hospitals
3 Lewis Gale Hospital Montgomery

Last Update: June 5, 2021.

Continuing Education Activity

Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can gradually restore volume and
stimulate collagen formation. It is FDA-approved for the correction of facial fat loss associated with antiretroviral
therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people to correct
nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck,
thighs, gluteal enhancement, and chest wall deformities, such as pectus excavatum or thoracic deformities secondary
to surgical procedures. This activity describes the mode of action of poly-L lactic acid, including modes of
administration, adverse event profiles, eligible patient populations, monitoring, and highlights the role of the
interprofessional team in the management of these patients.

Objectives:

Identify the mechanism of action of poly-L lactic acid.

Summarize the approved and off-label indications for poly-L lactic acid.

Outline the contraindications and adverse events associated with poly-L lactic acid.

Review interprofessional team strategies for improving care coordination and communication to advance poly-
L lactic acid and improve patient outcomes.

Access free multiple choice questions on this topic.

Indications
Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to gradually restore volume
and stimulate collagen formation. It is FDA-approved for the correction of facial fat loss associated with antiretroviral
therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people to correct
nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck,
thighs. It has also been used off-label for gluteal enhancement and chest wall deformities, such as pectus excavatum
or thoracic deformities secondary to surgical procedures. Poly-L-lactic acid has been reported to improve “step off”
chest wall deformities after mastectomy and implant reconstruction, suggesting that this product can also help
improve breast abnormalities. For maximal correction, a series of injections is recommended at 3 to 6-week intervals.
The degree of lipoatrophy correction is based on the number of sessions and not the volume injected at each session.
[1][2][3]

Mechanism of Action
Injection of poly-L-lactic acid into the deep dermis or subcutaneous tissue may cause an immediate augmentation of
the treated tissue. This is a temporary but immediate response due to tissue edema and fluid from the reconstitution of
the product. It will resolve within 2 to 3 days after injection. Once the carrier substance is absorbed, the poly-L-lactic
acid particles induce an inflammatory response through phagocytosis by tissue macrophages. This is a similar process
to suture reabsorption in the skin. The inflammatory response breaks down the poly-L-lactic acid into lactic acid
monomers. It is then metabolized to carbon dioxide and water while stimulating the production of new collagen type-I
fibers in the skin. Approximately half of the product is digested within 6 months. The duration of action is 12 to 24
months.[4][5][6]

Administration
Poly-L-lactic acid is microparticles of lyophilized, alpha-hydroxy acid polymers similar in structure to the polyglactin
910 suture material that comes in powder form. Poly-L-lactic acid comes in a carton containing 2 vials. Each vial
contains 367.5 g of product and is reconstituted with 4 mL of sterile water and 1 mL of lidocaine, producing a 5 mL
suspension of 4.45% poly-L-lactic acid. Higher dilution volumes can be used. Once diluted, it should be allowed to
stand undisturbed for 2 to 4 hours and swirled immediately before injection to ensure an even suspension of particles.
Some injectors recommend dilution 24 to 72 hours before injection to allow appropriate saturation of the powder. The
product does not require refrigeration once reconstituted. The poly-L-lactic acid is placed into the deep dermis or
subcutaneous tissue using a 26-gauge needle, roughly one vial per side of the face. Various injection techniques can
be used, including linear threading, depot injection in small volumes, and cross-hatching. Massage should be
performed during and after the injection to ensure an even distribution of the material. The patient should apply ice
packs to the treatment areas to reduce erythema and swelling.[7][8][9][10]

Adverse Effects
Acute injection site reaction is the most common adverse effect of this product. This can manifest as erythema,
swelling, or bruising that can take up to one week to heal. This risk increases if the patient takes a blood-thinning
agent, such as aspirin, warfarin, clopidogrel, apixaban, rivaroxaban, and dabigatran. Clinicians should carefully
review the patient’s medication list and counsel them regarding the increased risk.

Poly-L-lactic acid is a foreign substance. Therefore, it carries the risk of a hypersensitivity reaction upon injection in
the skin. Patients should remove all makeup, and the skin should be adequately prepped before injection to minimize
the introduction of additional foreign particles. Skin testing can be performed before treatment.

Post-treatment nodules with granuloma formation can occur with an injection of this product. The risk is thought to be
due to lower dilution volumes, and studies have shown that a decreased risk exists when dilution of volumes of 7 mL
or more are used. Post-injection massage recommended to be performed for 5 minutes at a time, 5 times a day for 5
days after injection, has been anecdotally recommended to help minimize the occurrence of the nodules. Injectors can
also place smaller aliquots of the product deeper in the skin to help minimize this risk. Several treatments can be
initiated if the patient experiences nodule formation. Early-onset lesions can be treated with subcision or injected with
sterile water. Later onset nodules can be treated with intralesional triamcinolone up to 40 mg/mL or 5-fluorouracil 2%
or 5% combined with a low-dose oral tetracycline antibiotic. There are some reports that oral prednisone may be used
to help suppress the formation of nodules.

Inappropriate placement of this product in the skin can lead to lumpiness or visibility of the filler through the skin.
Post-treatment massage to the area can help decrease this risk.

Post-procedural infection is rare but can occur. The skin should be prepped with an antiseptic, such as alcohol
followed by chlorhexidine or chloroxylenol. Some injectors inquire about a history of HSV and provide adequate
prophylaxis of antivirals up to 2 days before and 2 days after treatment if augmentation is performed on or around the
lip. 

The most feared complication of an injectable product is skin necrosis due to cannulation of the product into a vessel
with subsequent embolization or compression of a vessel from excessive volume. Injectors should have a thorough
understanding of the anatomy of the treatment area and be aware of any potential danger zones. Injection of low
volumes over multiple treatment sessions should be used whenever possible. Aspiration should be performed before
injecting the product into the tissue. In the event of a vascular compromise, methods to promote vasodilation should
be employed. The area should be treated with a warm compress and topical nitroglycerin to promote vasodilation.

Contraindications
Absolute contraindication to treatment is a known allergy to poly-L-lactic acid or any of its components. Injection
should not be performed if there is an active infection in the treatment area.

Monitoring
All patients should be assessed before treatment for facial asymmetry and volume differences. It is also important to
document any preexisting scars and inquire about a history of keloid formation. All patients should receive baseline
photographs and return for assessment 2 to 4 weeks after injection. Patients should be advised to avoid any
unnecessary herbal medications and supplements to decrease the risk of bruising. Anticoagulants should not be
discontinued.

Toxicity
There is no antidote to dissolve poly-L-lactic acid. In the event of a vascular compromise, methods to promote
vasodilation should be employed. The area should be treated with warm compresses and topical nitroglycerin to
promote vasodilation.

Enhancing Healthcare Team Outcomes

Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can gradually restore volume and
stimulate collagen formation. It is FDA-approved for the correction of facial fat loss associated with antiretroviral
therapy-induced lipoatrophy in HIV patients. While this dermal filler is usually only injected by dermatologists and
plastic surgeons, primary care providers and nurse practitioners should know which patients may benefit from poly-L-
lactic acid. Patients need to be educated about its side effects, potential complications, and durability. With open
communication between family clinicians, specialists, and nursing staff, patients can receive optimal benefits from
poly-L-lactic acid when indicated. [Level 5]

Review Questions

Access free multiple choice questions on this topic.

Comment on this article.

References
1. Lai Y, Li Y, Cao H, Long J, Wang X, Li L, Li C, Jia Q, Teng B, Tang T, Peng J, Eglin D, Alini M, Grijpma DW,
Richards G, Qin L. Osteogenic magnesium incorporated into PLGA/TCP porous scaffold by 3D printing for
repairing challenging bone defect. Biomaterials. 2019 Mar;197:207-219. [PubMed: 30660996]
2. Ibrahim O, Ionta S, Depina J, Petrell K, Arndt KA, Dover JS. Safety of Laser-Assisted Delivery of Topical Poly-
L-Lactic Acid in the Treatment of Upper Lip Rhytides: A Prospective, Rater-Blinded Study. Dermatol Surg. 2019
Jul;45(7):968-974. [PubMed: 30608292]
3. Alam M, Tung R. Injection technique in neurotoxins and fillers: Indications, products, and outcomes. J Am Acad
Dermatol. 2018 Sep;79(3):423-435. [PubMed: 30119866]
4. Herrmann JL, Hoffmann RK, Ward CE, Schulman JM, Grekin RC. Biochemistry, Physiology, and Tissue
Interactions of Contemporary Biodegradable Injectable Dermal Fillers. Dermatol Surg. 2018 Nov;44 Suppl 1:S19-
S31. [PubMed: 29994947]
5. Hotta TA. Attention to Infection Prevention in Medical Aesthetic Clinics. Plast Surg Nurs. 2018
Jan/Mar;38(1):17-24. [PubMed: 29494408]
6. Pascali M, Quarato D, Carinci F. Filling Procedures for Lip and Perioral Rejuvenation: A Systematic Review.
Rejuvenation Res. 2018 Dec;21(6):553-559. [PubMed: 29911505]
7. Fallacara A, Manfredini S, Durini E, Vertuani S. Hyaluronic Acid Fillers in Soft Tissue Regeneration. Facial Plast
Surg. 2017 Feb;33(1):87-96. [PubMed: 28226376]
8. Winslow C. Filling the Midface: Injectables. Facial Plast Surg. 2016 Oct;32(5):473-9. [PubMed: 27680518]
9. Sadick NS, Arruda S. The Use of Poly-L-Lactic Acid in the Abdominal Area. Dermatol Surg. 2017
Feb;43(2):313-315. [PubMed: 27598451]
10. Lee JC, Lorenc ZP. Synthetic Fillers for Facial Rejuvenation. Clin Plast Surg. 2016 Jul;43(3):497-503. [PubMed:
 27363763]

Copyright © 2022, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original
author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK507871 PMID: 29939648